nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxepin—ABCB1—esophageal cancer	0.351	1	CbGaD
Doxepin—HRH2—gastric juice—esophageal cancer	0.0412	0.36	CbGeAlD
Doxepin—HTR2A—vagus nerve—esophageal cancer	0.00701	0.0614	CbGeAlD
Doxepin—CHRM3—exocrine gland—esophageal cancer	0.00405	0.0355	CbGeAlD
Doxepin—CHRM5—epithelium—esophageal cancer	0.00315	0.0276	CbGeAlD
Doxepin—ADRA1D—epithelium—esophageal cancer	0.00282	0.0247	CbGeAlD
Doxepin—HRH2—digestive system—esophageal cancer	0.00251	0.022	CbGeAlD
Doxepin—HRH2—lung—esophageal cancer	0.0021	0.0184	CbGeAlD
Doxepin—HTR2B—smooth muscle tissue—esophageal cancer	0.00189	0.0165	CbGeAlD
Doxepin—CHRM1—trachea—esophageal cancer	0.00174	0.0152	CbGeAlD
Doxepin—CHRM3—smooth muscle tissue—esophageal cancer	0.0017	0.0149	CbGeAlD
Doxepin—ADRA1A—epithelium—esophageal cancer	0.00162	0.0142	CbGeAlD
Doxepin—HTR2A—neck—esophageal cancer	0.00154	0.0135	CbGeAlD
Doxepin—ADRA2C—bronchus—esophageal cancer	0.00152	0.0133	CbGeAlD
Doxepin—SLC6A4—digestive system—esophageal cancer	0.0015	0.0132	CbGeAlD
Doxepin—HTR2B—digestive system—esophageal cancer	0.00149	0.013	CbGeAlD
Doxepin—ORM1—lung—esophageal cancer	0.00148	0.0129	CbGeAlD
Doxepin—HRH2—lymph node—esophageal cancer	0.00143	0.0126	CbGeAlD
Doxepin—ADRA2C—trachea—esophageal cancer	0.00136	0.0119	CbGeAlD
Doxepin—CHRM3—digestive system—esophageal cancer	0.00134	0.0117	CbGeAlD
Doxepin—SLC6A4—lung—esophageal cancer	0.00126	0.011	CbGeAlD
Doxepin—HRH1—epithelium—esophageal cancer	0.00125	0.011	CbGeAlD
Doxepin—CHRM1—lung—esophageal cancer	0.00125	0.011	CbGeAlD
Doxepin—CYP2C19—digestive system—esophageal cancer	0.00125	0.0109	CbGeAlD
Doxepin—HTR2B—lung—esophageal cancer	0.00125	0.0109	CbGeAlD
Doxepin—ADRA2A—bronchus—esophageal cancer	0.00121	0.0106	CbGeAlD
Doxepin—HRH1—smooth muscle tissue—esophageal cancer	0.00121	0.0106	CbGeAlD
Doxepin—HRH1—trachea—esophageal cancer	0.00111	0.0097	CbGeAlD
Doxepin—SLC6A2—lung—esophageal cancer	0.00111	0.00968	CbGeAlD
Doxepin—ADRA2A—trachea—esophageal cancer	0.00109	0.00953	CbGeAlD
Doxepin—HTR2A—epithelium—esophageal cancer	0.00105	0.00916	CbGeAlD
Doxepin—CYP1A2—digestive system—esophageal cancer	0.00102	0.00891	CbGeAlD
Doxepin—ORM1—lymph node—esophageal cancer	0.00101	0.00883	CbGeAlD
Doxepin—HTR2A—smooth muscle tissue—esophageal cancer	0.00101	0.00883	CbGeAlD
Doxepin—DRD2—lung—esophageal cancer	0.00101	0.00882	CbGeAlD
Doxepin—ADRA2C—lung—esophageal cancer	0.00098	0.00858	CbGeAlD
Doxepin—CYP2C9—digestive system—esophageal cancer	0.000967	0.00846	CbGeAlD
Doxepin—Libido decreased—Capecitabine—esophageal cancer	0.00096	0.00383	CcSEcCtD
Doxepin—HRH1—digestive system—esophageal cancer	0.000953	0.00834	CbGeAlD
Doxepin—Hot flush—Capecitabine—esophageal cancer	0.000951	0.0038	CcSEcCtD
Doxepin—Increased appetite—Capecitabine—esophageal cancer	0.000947	0.00378	CcSEcCtD
Doxepin—Menopausal symptoms—Capecitabine—esophageal cancer	0.000943	0.00376	CcSEcCtD
Doxepin—HTR2A—trachea—esophageal cancer	0.000926	0.0081	CbGeAlD
Doxepin—Purpura—Capecitabine—esophageal cancer	0.000923	0.00368	CcSEcCtD
Doxepin—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000912	0.00364	CcSEcCtD
Doxepin—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000908	0.00362	CcSEcCtD
Doxepin—Lethargy—Capecitabine—esophageal cancer	0.000908	0.00362	CcSEcCtD
Doxepin—Stomatitis—Cisplatin—esophageal cancer	0.000907	0.00362	CcSEcCtD
Doxepin—Diplopia—Capecitabine—esophageal cancer	0.00089	0.00355	CcSEcCtD
Doxepin—Pain in extremity—Capecitabine—esophageal cancer	0.00089	0.00355	CcSEcCtD
Doxepin—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000883	0.00352	CcSEcCtD
Doxepin—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00088	0.00351	CcSEcCtD
Doxepin—Migraine—Capecitabine—esophageal cancer	0.000876	0.00349	CcSEcCtD
Doxepin—HTR2B—lymph node—esophageal cancer	0.000852	0.00745	CbGeAlD
Doxepin—CYP1A2—lung—esophageal cancer	0.000851	0.00744	CbGeAlD
Doxepin—Bradycardia—Cisplatin—esophageal cancer	0.00085	0.00339	CcSEcCtD
Doxepin—Urinary retention—Capecitabine—esophageal cancer	0.000846	0.00338	CcSEcCtD
Doxepin—Ataxia—Capecitabine—esophageal cancer	0.000837	0.00334	CcSEcCtD
Doxepin—Neoplasm—Methotrexate—esophageal cancer	0.000825	0.00329	CcSEcCtD
Doxepin—Urinary tract disorder—Cisplatin—esophageal cancer	0.000825	0.00329	CcSEcCtD
Doxepin—Connective tissue disorder—Cisplatin—esophageal cancer	0.000821	0.00327	CcSEcCtD
Doxepin—Urethral disorder—Cisplatin—esophageal cancer	0.000819	0.00327	CcSEcCtD
Doxepin—Gynaecomastia—Methotrexate—esophageal cancer	0.000817	0.00326	CcSEcCtD
Doxepin—Hypokalaemia—Capecitabine—esophageal cancer	0.00081	0.00323	CcSEcCtD
Doxepin—Breast disorder—Capecitabine—esophageal cancer	0.000804	0.00321	CcSEcCtD
Doxepin—HTR2A—digestive system—esophageal cancer	0.000796	0.00697	CbGeAlD
Doxepin—HRH1—lung—esophageal cancer	0.000796	0.00697	CbGeAlD
Doxepin—Nasopharyngitis—Capecitabine—esophageal cancer	0.000796	0.00317	CcSEcCtD
Doxepin—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000785	0.00313	CcSEcCtD
Doxepin—ADRA2A—lung—esophageal cancer	0.000782	0.00684	CbGeAlD
Doxepin—Eye disorder—Cisplatin—esophageal cancer	0.00078	0.00311	CcSEcCtD
Doxepin—Tinnitus—Cisplatin—esophageal cancer	0.000779	0.00311	CcSEcCtD
Doxepin—Flushing—Cisplatin—esophageal cancer	0.000775	0.00309	CcSEcCtD
Doxepin—Cardiac disorder—Cisplatin—esophageal cancer	0.000775	0.00309	CcSEcCtD
Doxepin—Asthma—Capecitabine—esophageal cancer	0.000769	0.00307	CcSEcCtD
Doxepin—Influenza—Capecitabine—esophageal cancer	0.000769	0.00307	CcSEcCtD
Doxepin—SLC6A2—lymph node—esophageal cancer	0.000757	0.00662	CbGeAlD
Doxepin—Immune system disorder—Cisplatin—esophageal cancer	0.000754	0.00301	CcSEcCtD
Doxepin—Mediastinal disorder—Cisplatin—esophageal cancer	0.000753	0.003	CcSEcCtD
Doxepin—Arrhythmia—Cisplatin—esophageal cancer	0.000746	0.00298	CcSEcCtD
Doxepin—Bronchitis—Capecitabine—esophageal cancer	0.00074	0.00295	CcSEcCtD
Doxepin—Alopecia—Cisplatin—esophageal cancer	0.000738	0.00294	CcSEcCtD
Doxepin—CYP3A4—digestive system—esophageal cancer	0.000737	0.00645	CbGeAlD
Doxepin—Pancytopenia—Capecitabine—esophageal cancer	0.00073	0.00291	CcSEcCtD
Doxepin—Malnutrition—Cisplatin—esophageal cancer	0.000727	0.0029	CcSEcCtD
Doxepin—Erythema—Cisplatin—esophageal cancer	0.000727	0.0029	CcSEcCtD
Doxepin—CYP2D6—digestive system—esophageal cancer	0.000725	0.00635	CbGeAlD
Doxepin—Dysuria—Capecitabine—esophageal cancer	0.000719	0.00287	CcSEcCtD
Doxepin—Flatulence—Cisplatin—esophageal cancer	0.000716	0.00286	CcSEcCtD
Doxepin—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000715	0.00285	CcSEcCtD
Doxepin—Weight increased—Capecitabine—esophageal cancer	0.0007	0.00279	CcSEcCtD
Doxepin—Muscle spasms—Cisplatin—esophageal cancer	0.000699	0.00279	CcSEcCtD
Doxepin—Pneumonia—Capecitabine—esophageal cancer	0.00069	0.00275	CcSEcCtD
Doxepin—ABCB1—epithelium—esophageal cancer	0.000686	0.006	CbGeAlD
Doxepin—Infestation—Capecitabine—esophageal cancer	0.000686	0.00274	CcSEcCtD
Doxepin—Infestation NOS—Capecitabine—esophageal cancer	0.000686	0.00274	CcSEcCtD
Doxepin—Vision blurred—Cisplatin—esophageal cancer	0.000685	0.00273	CcSEcCtD
Doxepin—Tremor—Cisplatin—esophageal cancer	0.000681	0.00272	CcSEcCtD
Doxepin—KCNH2—lymph node—esophageal cancer	0.00068	0.00595	CbGeAlD
Doxepin—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000676	0.0027	CcSEcCtD
Doxepin—Lethargy—Methotrexate—esophageal cancer	0.000676	0.0027	CcSEcCtD
Doxepin—Ill-defined disorder—Cisplatin—esophageal cancer	0.000675	0.00269	CcSEcCtD
Doxepin—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000672	0.00268	CcSEcCtD
Doxepin—Anaemia—Cisplatin—esophageal cancer	0.000672	0.00268	CcSEcCtD
Doxepin—ADRA2C—lymph node—esophageal cancer	0.00067	0.00587	CbGeAlD
Doxepin—Jaundice—Capecitabine—esophageal cancer	0.000668	0.00267	CcSEcCtD
Doxepin—Stomatitis—Capecitabine—esophageal cancer	0.000668	0.00267	CcSEcCtD
Doxepin—Urinary tract infection—Capecitabine—esophageal cancer	0.000667	0.00266	CcSEcCtD
Doxepin—HTR2A—lung—esophageal cancer	0.000665	0.00582	CbGeAlD
Doxepin—Malaise—Cisplatin—esophageal cancer	0.000656	0.00262	CcSEcCtD
Doxepin—Leukopenia—Cisplatin—esophageal cancer	0.000651	0.0026	CcSEcCtD
Doxepin—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000649	0.00259	CcSEcCtD
Doxepin—Agranulocytosis—Capecitabine—esophageal cancer	0.00064	0.00255	CcSEcCtD
Doxepin—Convulsion—Cisplatin—esophageal cancer	0.00063	0.00251	CcSEcCtD
Doxepin—Bradycardia—Capecitabine—esophageal cancer	0.000627	0.0025	CcSEcCtD
Doxepin—Ataxia—Methotrexate—esophageal cancer	0.000623	0.00249	CcSEcCtD
Doxepin—Myalgia—Cisplatin—esophageal cancer	0.000619	0.00247	CcSEcCtD
Doxepin—Anxiety—Cisplatin—esophageal cancer	0.000617	0.00246	CcSEcCtD
Doxepin—Hepatitis—Capecitabine—esophageal cancer	0.000616	0.00246	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000615	0.00245	CcSEcCtD
Doxepin—Hypoaesthesia—Capecitabine—esophageal cancer	0.000613	0.00244	CcSEcCtD
Doxepin—Discomfort—Cisplatin—esophageal cancer	0.000612	0.00244	CcSEcCtD
Doxepin—Pharyngitis—Capecitabine—esophageal cancer	0.000611	0.00244	CcSEcCtD
Doxepin—Urinary tract disorder—Capecitabine—esophageal cancer	0.000608	0.00243	CcSEcCtD
Doxepin—ABCB1—trachea—esophageal cancer	0.000607	0.00531	CbGeAlD
Doxepin—Oedema peripheral—Capecitabine—esophageal cancer	0.000606	0.00242	CcSEcCtD
Doxepin—Connective tissue disorder—Capecitabine—esophageal cancer	0.000605	0.00241	CcSEcCtD
Doxepin—Urethral disorder—Capecitabine—esophageal cancer	0.000603	0.00241	CcSEcCtD
Doxepin—Breast disorder—Methotrexate—esophageal cancer	0.000599	0.00239	CcSEcCtD
Doxepin—Oedema—Cisplatin—esophageal cancer	0.000593	0.00237	CcSEcCtD
Doxepin—Infection—Cisplatin—esophageal cancer	0.000589	0.00235	CcSEcCtD
Doxepin—Nervous system disorder—Cisplatin—esophageal cancer	0.000582	0.00232	CcSEcCtD
Doxepin—Thrombocytopenia—Cisplatin—esophageal cancer	0.000581	0.00232	CcSEcCtD
Doxepin—Tachycardia—Cisplatin—esophageal cancer	0.000579	0.00231	CcSEcCtD
Doxepin—Skin disorder—Cisplatin—esophageal cancer	0.000576	0.0023	CcSEcCtD
Doxepin—Eye disorder—Capecitabine—esophageal cancer	0.000575	0.0023	CcSEcCtD
Doxepin—Tinnitus—Capecitabine—esophageal cancer	0.000574	0.00229	CcSEcCtD
Doxepin—Hyperhidrosis—Cisplatin—esophageal cancer	0.000574	0.00229	CcSEcCtD
Doxepin—Asthma—Methotrexate—esophageal cancer	0.000573	0.00228	CcSEcCtD
Doxepin—Cardiac disorder—Capecitabine—esophageal cancer	0.000571	0.00228	CcSEcCtD
Doxepin—Flushing—Capecitabine—esophageal cancer	0.000571	0.00228	CcSEcCtD
Doxepin—Eosinophilia—Methotrexate—esophageal cancer	0.000567	0.00226	CcSEcCtD
Doxepin—Anorexia—Cisplatin—esophageal cancer	0.000566	0.00226	CcSEcCtD
Doxepin—Angiopathy—Capecitabine—esophageal cancer	0.000559	0.00223	CcSEcCtD
Doxepin—Immune system disorder—Capecitabine—esophageal cancer	0.000556	0.00222	CcSEcCtD
Doxepin—Mediastinal disorder—Capecitabine—esophageal cancer	0.000555	0.00221	CcSEcCtD
Doxepin—Hypotension—Cisplatin—esophageal cancer	0.000554	0.00221	CcSEcCtD
Doxepin—Chills—Capecitabine—esophageal cancer	0.000552	0.0022	CcSEcCtD
Doxepin—Arrhythmia—Capecitabine—esophageal cancer	0.00055	0.00219	CcSEcCtD
Doxepin—HRH1—lymph node—esophageal cancer	0.000545	0.00477	CbGeAlD
Doxepin—Alopecia—Capecitabine—esophageal cancer	0.000544	0.00217	CcSEcCtD
Doxepin—Pancytopenia—Methotrexate—esophageal cancer	0.000544	0.00217	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000541	0.00216	CcSEcCtD
Doxepin—Mental disorder—Capecitabine—esophageal cancer	0.000539	0.00215	CcSEcCtD
Doxepin—Malnutrition—Capecitabine—esophageal cancer	0.000536	0.00214	CcSEcCtD
Doxepin—Erythema—Capecitabine—esophageal cancer	0.000536	0.00214	CcSEcCtD
Doxepin—Dysuria—Methotrexate—esophageal cancer	0.000535	0.00214	CcSEcCtD
Doxepin—ADRA2A—lymph node—esophageal cancer	0.000535	0.00468	CbGeAlD
Doxepin—Paraesthesia—Cisplatin—esophageal cancer	0.000533	0.00213	CcSEcCtD
Doxepin—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000532	0.00212	CcSEcCtD
Doxepin—Dyspnoea—Cisplatin—esophageal cancer	0.000529	0.00211	CcSEcCtD
Doxepin—Flatulence—Capecitabine—esophageal cancer	0.000528	0.00211	CcSEcCtD
Doxepin—Erectile dysfunction—Methotrexate—esophageal cancer	0.000527	0.0021	CcSEcCtD
Doxepin—Dysgeusia—Capecitabine—esophageal cancer	0.000525	0.00209	CcSEcCtD
Doxepin—ABCB1—digestive system—esophageal cancer	0.000522	0.00457	CbGeAlD
Doxepin—Back pain—Capecitabine—esophageal cancer	0.000518	0.00207	CcSEcCtD
Doxepin—Decreased appetite—Cisplatin—esophageal cancer	0.000516	0.00206	CcSEcCtD
Doxepin—Muscle spasms—Capecitabine—esophageal cancer	0.000515	0.00206	CcSEcCtD
Doxepin—Pneumonia—Methotrexate—esophageal cancer	0.000513	0.00205	CcSEcCtD
Doxepin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000512	0.00204	CcSEcCtD
Doxepin—Drowsiness—Methotrexate—esophageal cancer	0.000511	0.00204	CcSEcCtD
Doxepin—Infestation NOS—Methotrexate—esophageal cancer	0.000511	0.00204	CcSEcCtD
Doxepin—Infestation—Methotrexate—esophageal cancer	0.000511	0.00204	CcSEcCtD
Doxepin—Pain—Cisplatin—esophageal cancer	0.000507	0.00202	CcSEcCtD
Doxepin—Vision blurred—Capecitabine—esophageal cancer	0.000505	0.00202	CcSEcCtD
Doxepin—Tremor—Capecitabine—esophageal cancer	0.000502	0.002	CcSEcCtD
Doxepin—Stomatitis—Methotrexate—esophageal cancer	0.000498	0.00199	CcSEcCtD
Doxepin—Ill-defined disorder—Capecitabine—esophageal cancer	0.000497	0.00198	CcSEcCtD
Doxepin—Anaemia—Capecitabine—esophageal cancer	0.000495	0.00198	CcSEcCtD
Doxepin—Sweating—Methotrexate—esophageal cancer	0.000489	0.00195	CcSEcCtD
Doxepin—Feeling abnormal—Cisplatin—esophageal cancer	0.000489	0.00195	CcSEcCtD
Doxepin—Malaise—Capecitabine—esophageal cancer	0.000483	0.00193	CcSEcCtD
Doxepin—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000483	0.00193	CcSEcCtD
Doxepin—Vertigo—Capecitabine—esophageal cancer	0.000481	0.00192	CcSEcCtD
Doxepin—Syncope—Capecitabine—esophageal cancer	0.000481	0.00192	CcSEcCtD
Doxepin—Leukopenia—Capecitabine—esophageal cancer	0.00048	0.00191	CcSEcCtD
Doxepin—Agranulocytosis—Methotrexate—esophageal cancer	0.000476	0.0019	CcSEcCtD
Doxepin—Palpitations—Capecitabine—esophageal cancer	0.000474	0.00189	CcSEcCtD
Doxepin—Loss of consciousness—Capecitabine—esophageal cancer	0.000471	0.00188	CcSEcCtD
Doxepin—Body temperature increased—Cisplatin—esophageal cancer	0.000469	0.00187	CcSEcCtD
Doxepin—Cough—Capecitabine—esophageal cancer	0.000468	0.00187	CcSEcCtD
Doxepin—Hypertension—Capecitabine—esophageal cancer	0.000463	0.00185	CcSEcCtD
Doxepin—Hepatitis—Methotrexate—esophageal cancer	0.000458	0.00183	CcSEcCtD
Doxepin—Arthralgia—Capecitabine—esophageal cancer	0.000456	0.00182	CcSEcCtD
Doxepin—Chest pain—Capecitabine—esophageal cancer	0.000456	0.00182	CcSEcCtD
Doxepin—Myalgia—Capecitabine—esophageal cancer	0.000456	0.00182	CcSEcCtD
Doxepin—Pharyngitis—Methotrexate—esophageal cancer	0.000455	0.00181	CcSEcCtD
Doxepin—Anxiety—Capecitabine—esophageal cancer	0.000455	0.00181	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000453	0.00181	CcSEcCtD
Doxepin—Urinary tract disorder—Methotrexate—esophageal cancer	0.000453	0.00181	CcSEcCtD
Doxepin—Discomfort—Capecitabine—esophageal cancer	0.000451	0.0018	CcSEcCtD
Doxepin—Urethral disorder—Methotrexate—esophageal cancer	0.000449	0.00179	CcSEcCtD
Doxepin—Dry mouth—Capecitabine—esophageal cancer	0.000446	0.00178	CcSEcCtD
Doxepin—Confusional state—Capecitabine—esophageal cancer	0.000441	0.00176	CcSEcCtD
Doxepin—Oedema—Capecitabine—esophageal cancer	0.000437	0.00175	CcSEcCtD
Doxepin—Hypersensitivity—Cisplatin—esophageal cancer	0.000437	0.00174	CcSEcCtD
Doxepin—ABCB1—lung—esophageal cancer	0.000436	0.00381	CbGeAlD
Doxepin—Infection—Capecitabine—esophageal cancer	0.000435	0.00173	CcSEcCtD
Doxepin—Shock—Capecitabine—esophageal cancer	0.00043	0.00172	CcSEcCtD
Doxepin—Nervous system disorder—Capecitabine—esophageal cancer	0.000429	0.00171	CcSEcCtD
Doxepin—Eye disorder—Methotrexate—esophageal cancer	0.000428	0.00171	CcSEcCtD
Doxepin—Thrombocytopenia—Capecitabine—esophageal cancer	0.000428	0.00171	CcSEcCtD
Doxepin—Tinnitus—Methotrexate—esophageal cancer	0.000427	0.0017	CcSEcCtD
Doxepin—Tachycardia—Capecitabine—esophageal cancer	0.000427	0.0017	CcSEcCtD
Doxepin—Asthenia—Cisplatin—esophageal cancer	0.000426	0.0017	CcSEcCtD
Doxepin—Cardiac disorder—Methotrexate—esophageal cancer	0.000425	0.0017	CcSEcCtD
Doxepin—Skin disorder—Capecitabine—esophageal cancer	0.000425	0.00169	CcSEcCtD
Doxepin—Hyperhidrosis—Capecitabine—esophageal cancer	0.000423	0.00169	CcSEcCtD
Doxepin—Anorexia—Capecitabine—esophageal cancer	0.000417	0.00166	CcSEcCtD
Doxepin—Angiopathy—Methotrexate—esophageal cancer	0.000416	0.00166	CcSEcCtD
Doxepin—Immune system disorder—Methotrexate—esophageal cancer	0.000414	0.00165	CcSEcCtD
Doxepin—Mediastinal disorder—Methotrexate—esophageal cancer	0.000413	0.00165	CcSEcCtD
Doxepin—Chills—Methotrexate—esophageal cancer	0.000411	0.00164	CcSEcCtD
Doxepin—Hypotension—Capecitabine—esophageal cancer	0.000409	0.00163	CcSEcCtD
Doxepin—Diarrhoea—Cisplatin—esophageal cancer	0.000406	0.00162	CcSEcCtD
Doxepin—Alopecia—Methotrexate—esophageal cancer	0.000405	0.00162	CcSEcCtD
Doxepin—Mental disorder—Methotrexate—esophageal cancer	0.000402	0.0016	CcSEcCtD
Doxepin—Erythema—Methotrexate—esophageal cancer	0.000399	0.00159	CcSEcCtD
Doxepin—Malnutrition—Methotrexate—esophageal cancer	0.000399	0.00159	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000398	0.00159	CcSEcCtD
Doxepin—Insomnia—Capecitabine—esophageal cancer	0.000396	0.00158	CcSEcCtD
Doxepin—Paraesthesia—Capecitabine—esophageal cancer	0.000393	0.00157	CcSEcCtD
Doxepin—Dysgeusia—Methotrexate—esophageal cancer	0.000391	0.00156	CcSEcCtD
Doxepin—Dyspnoea—Capecitabine—esophageal cancer	0.00039	0.00156	CcSEcCtD
Doxepin—Back pain—Methotrexate—esophageal cancer	0.000386	0.00154	CcSEcCtD
Doxepin—Dyspepsia—Capecitabine—esophageal cancer	0.000385	0.00154	CcSEcCtD
Doxepin—Decreased appetite—Capecitabine—esophageal cancer	0.00038	0.00152	CcSEcCtD
Doxepin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000378	0.00151	CcSEcCtD
Doxepin—Vomiting—Cisplatin—esophageal cancer	0.000377	0.00151	CcSEcCtD
Doxepin—Fatigue—Capecitabine—esophageal cancer	0.000377	0.0015	CcSEcCtD
Doxepin—Vision blurred—Methotrexate—esophageal cancer	0.000376	0.0015	CcSEcCtD
Doxepin—Rash—Cisplatin—esophageal cancer	0.000374	0.00149	CcSEcCtD
Doxepin—Constipation—Capecitabine—esophageal cancer	0.000374	0.00149	CcSEcCtD
Doxepin—Pain—Capecitabine—esophageal cancer	0.000374	0.00149	CcSEcCtD
Doxepin—Dermatitis—Cisplatin—esophageal cancer	0.000374	0.00149	CcSEcCtD
Doxepin—Ill-defined disorder—Methotrexate—esophageal cancer	0.00037	0.00148	CcSEcCtD
Doxepin—Anaemia—Methotrexate—esophageal cancer	0.000369	0.00147	CcSEcCtD
Doxepin—Feeling abnormal—Capecitabine—esophageal cancer	0.00036	0.00144	CcSEcCtD
Doxepin—Malaise—Methotrexate—esophageal cancer	0.00036	0.00144	CcSEcCtD
Doxepin—Vertigo—Methotrexate—esophageal cancer	0.000358	0.00143	CcSEcCtD
Doxepin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000358	0.00143	CcSEcCtD
Doxepin—Leukopenia—Methotrexate—esophageal cancer	0.000357	0.00142	CcSEcCtD
Doxepin—Nausea—Cisplatin—esophageal cancer	0.000352	0.00141	CcSEcCtD
Doxepin—Cough—Methotrexate—esophageal cancer	0.000348	0.00139	CcSEcCtD
Doxepin—Urticaria—Capecitabine—esophageal cancer	0.000347	0.00139	CcSEcCtD
Doxepin—Abdominal pain—Capecitabine—esophageal cancer	0.000346	0.00138	CcSEcCtD
Doxepin—Body temperature increased—Capecitabine—esophageal cancer	0.000346	0.00138	CcSEcCtD
Doxepin—Convulsion—Methotrexate—esophageal cancer	0.000346	0.00138	CcSEcCtD
Doxepin—Desipramine—CYP2A6—esophageal cancer	0.000341	0.18	CrCbGaD
Doxepin—Chest pain—Methotrexate—esophageal cancer	0.00034	0.00136	CcSEcCtD
Doxepin—Myalgia—Methotrexate—esophageal cancer	0.00034	0.00136	CcSEcCtD
Doxepin—Arthralgia—Methotrexate—esophageal cancer	0.00034	0.00136	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000337	0.00135	CcSEcCtD
Doxepin—Discomfort—Methotrexate—esophageal cancer	0.000336	0.00134	CcSEcCtD
Doxepin—Confusional state—Methotrexate—esophageal cancer	0.000328	0.00131	CcSEcCtD
Doxepin—Infection—Methotrexate—esophageal cancer	0.000323	0.00129	CcSEcCtD
Doxepin—Hypersensitivity—Capecitabine—esophageal cancer	0.000322	0.00129	CcSEcCtD
Doxepin—Nervous system disorder—Methotrexate—esophageal cancer	0.000319	0.00127	CcSEcCtD
Doxepin—Thrombocytopenia—Methotrexate—esophageal cancer	0.000319	0.00127	CcSEcCtD
Doxepin—Nortriptyline—PTGS1—esophageal cancer	0.000317	0.168	CrCbGaD
Doxepin—Skin disorder—Methotrexate—esophageal cancer	0.000316	0.00126	CcSEcCtD
Doxepin—Hyperhidrosis—Methotrexate—esophageal cancer	0.000315	0.00126	CcSEcCtD
Doxepin—Asthenia—Capecitabine—esophageal cancer	0.000314	0.00125	CcSEcCtD
Doxepin—Anorexia—Methotrexate—esophageal cancer	0.00031	0.00124	CcSEcCtD
Doxepin—Pruritus—Capecitabine—esophageal cancer	0.000309	0.00123	CcSEcCtD
Doxepin—Hypotension—Methotrexate—esophageal cancer	0.000304	0.00121	CcSEcCtD
Doxepin—Diarrhoea—Capecitabine—esophageal cancer	0.000299	0.00119	CcSEcCtD
Doxepin—ABCB1—lymph node—esophageal cancer	0.000298	0.00261	CbGeAlD
Doxepin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000297	0.00118	CcSEcCtD
Doxepin—Insomnia—Methotrexate—esophageal cancer	0.000294	0.00117	CcSEcCtD
Doxepin—Diphenhydramine—PTGS1—esophageal cancer	0.000293	0.155	CrCbGaD
Doxepin—Paraesthesia—Methotrexate—esophageal cancer	0.000292	0.00117	CcSEcCtD
Doxepin—Dyspnoea—Methotrexate—esophageal cancer	0.00029	0.00116	CcSEcCtD
Doxepin—Somnolence—Methotrexate—esophageal cancer	0.000289	0.00115	CcSEcCtD
Doxepin—Dizziness—Capecitabine—esophageal cancer	0.000289	0.00115	CcSEcCtD
Doxepin—Dyspepsia—Methotrexate—esophageal cancer	0.000287	0.00114	CcSEcCtD
Doxepin—Decreased appetite—Methotrexate—esophageal cancer	0.000283	0.00113	CcSEcCtD
Doxepin—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000281	0.00112	CcSEcCtD
Doxepin—Fatigue—Methotrexate—esophageal cancer	0.000281	0.00112	CcSEcCtD
Doxepin—Pain—Methotrexate—esophageal cancer	0.000278	0.00111	CcSEcCtD
Doxepin—Vomiting—Capecitabine—esophageal cancer	0.000278	0.00111	CcSEcCtD
Doxepin—Rash—Capecitabine—esophageal cancer	0.000276	0.0011	CcSEcCtD
Doxepin—Dermatitis—Capecitabine—esophageal cancer	0.000276	0.0011	CcSEcCtD
Doxepin—Headache—Capecitabine—esophageal cancer	0.000274	0.00109	CcSEcCtD
Doxepin—Feeling abnormal—Methotrexate—esophageal cancer	0.000268	0.00107	CcSEcCtD
Doxepin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000266	0.00106	CcSEcCtD
Doxepin—Nausea—Capecitabine—esophageal cancer	0.00026	0.00104	CcSEcCtD
Doxepin—Urticaria—Methotrexate—esophageal cancer	0.000259	0.00103	CcSEcCtD
Doxepin—Abdominal pain—Methotrexate—esophageal cancer	0.000257	0.00103	CcSEcCtD
Doxepin—Body temperature increased—Methotrexate—esophageal cancer	0.000257	0.00103	CcSEcCtD
Doxepin—Hypersensitivity—Methotrexate—esophageal cancer	0.00024	0.000957	CcSEcCtD
Doxepin—Asthenia—Methotrexate—esophageal cancer	0.000234	0.000932	CcSEcCtD
Doxepin—Pruritus—Methotrexate—esophageal cancer	0.00023	0.000919	CcSEcCtD
Doxepin—Diarrhoea—Methotrexate—esophageal cancer	0.000223	0.000889	CcSEcCtD
Doxepin—Dizziness—Methotrexate—esophageal cancer	0.000215	0.000859	CcSEcCtD
Doxepin—Vomiting—Methotrexate—esophageal cancer	0.000207	0.000826	CcSEcCtD
Doxepin—Rash—Methotrexate—esophageal cancer	0.000205	0.000819	CcSEcCtD
Doxepin—Dermatitis—Methotrexate—esophageal cancer	0.000205	0.000818	CcSEcCtD
Doxepin—Headache—Methotrexate—esophageal cancer	0.000204	0.000814	CcSEcCtD
Doxepin—Nausea—Methotrexate—esophageal cancer	0.000193	0.000772	CcSEcCtD
Doxepin—Clomipramine—ABCB1—esophageal cancer	0.000158	0.0833	CrCbGaD
Doxepin—Chlorprothixene—ABCB1—esophageal cancer	0.000157	0.083	CrCbGaD
Doxepin—Trimipramine—ABCB1—esophageal cancer	0.000145	0.0767	CrCbGaD
Doxepin—Promethazine—ABCB1—esophageal cancer	0.00014	0.0738	CrCbGaD
Doxepin—Desipramine—ABCB1—esophageal cancer	0.000127	0.067	CrCbGaD
Doxepin—Imipramine—ABCB1—esophageal cancer	0.000108	0.0569	CrCbGaD
Doxepin—Amitriptyline—ABCB1—esophageal cancer	0.000107	0.0565	CrCbGaD
Doxepin—ADRA2A—Signaling Pathways—KDR—esophageal cancer	1.25e-05	4.45e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—EP300—esophageal cancer	1.25e-05	4.45e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—NOS3—esophageal cancer	1.25e-05	4.43e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.25e-05	4.43e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.24e-05	4.41e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—CCND1—esophageal cancer	1.24e-05	4.41e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—CDKN1A—esophageal cancer	1.24e-05	4.41e-05	CbGpPWpGaD
Doxepin—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	1.24e-05	4.39e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.24e-05	4.39e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—CCND1—esophageal cancer	1.23e-05	4.36e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.23e-05	4.36e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—NOS3—esophageal cancer	1.22e-05	4.33e-05	CbGpPWpGaD
Doxepin—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.22e-05	4.32e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—NOS3—esophageal cancer	1.21e-05	4.3e-05	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—PIK3CA—esophageal cancer	1.21e-05	4.29e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.21e-05	4.28e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	1.2e-05	4.27e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	1.2e-05	4.27e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—CREBBP—esophageal cancer	1.2e-05	4.24e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—CDKN1A—esophageal cancer	1.19e-05	4.22e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—EP300—esophageal cancer	1.18e-05	4.19e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	1.18e-05	4.19e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	1.18e-05	4.19e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	1.18e-05	4.19e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	1.18e-05	4.18e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—EGFR—esophageal cancer	1.18e-05	4.17e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—CREBBP—esophageal cancer	1.17e-05	4.17e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	1.17e-05	4.15e-05	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—TP53—esophageal cancer	1.17e-05	4.15e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—CREBBP—esophageal cancer	1.17e-05	4.14e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.17e-05	4.14e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—ENO1—esophageal cancer	1.17e-05	4.14e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.16e-05	4.12e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	1.16e-05	4.12e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—CCND1—esophageal cancer	1.16e-05	4.1e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	1.16e-05	4.1e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.16e-05	4.1e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—CREBBP—esophageal cancer	1.16e-05	4.1e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—EGFR—esophageal cancer	1.15e-05	4.09e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	1.15e-05	4.09e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	1.15e-05	4.08e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PSME2—esophageal cancer	1.15e-05	4.08e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PSME1—esophageal cancer	1.15e-05	4.08e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—EGFR—esophageal cancer	1.15e-05	4.07e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—NOS3—esophageal cancer	1.15e-05	4.07e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—EP300—esophageal cancer	1.14e-05	4.06e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—PTGS2—esophageal cancer	1.14e-05	4.05e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	1.14e-05	4.05e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—EGFR—esophageal cancer	1.14e-05	4.03e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	1.14e-05	4.03e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	1.13e-05	4.02e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—EP300—esophageal cancer	1.13e-05	4.02e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.12e-05	3.99e-05	CbGpPWpGaD
Doxepin—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.12e-05	3.99e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—CDKN1A—esophageal cancer	1.12e-05	3.97e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	1.11e-05	3.93e-05	CbGpPWpGaD
Doxepin—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.11e-05	3.92e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	1.1e-05	3.92e-05	CbGpPWpGaD
Doxepin—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.1e-05	3.91e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.1e-05	3.91e-05	CbGpPWpGaD
Doxepin—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.1e-05	3.9e-05	CbGpPWpGaD
Doxepin—CHRM3—GPCR downstream signaling—PIK3CA—esophageal cancer	1.1e-05	3.89e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—MYC—esophageal cancer	1.09e-05	3.87e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	1.09e-05	3.85e-05	CbGpPWpGaD
Doxepin—CHRM2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.09e-05	3.85e-05	CbGpPWpGaD
Doxepin—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.08e-05	3.84e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.08e-05	3.83e-05	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—EP300—esophageal cancer	1.07e-05	3.81e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—NOS3—esophageal cancer	1.07e-05	3.8e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	1.07e-05	3.8e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—EGFR—esophageal cancer	1.07e-05	3.79e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—EP300—esophageal cancer	1.06e-05	3.78e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.06e-05	3.75e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—NOS3—esophageal cancer	1.05e-05	3.74e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	1.05e-05	3.73e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—NOS3—esophageal cancer	1.05e-05	3.73e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—PTGS2—esophageal cancer	1.05e-05	3.72e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—NOS3—esophageal cancer	1.05e-05	3.72e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—NOS3—esophageal cancer	1.04e-05	3.71e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	1.04e-05	3.7e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—NOS3—esophageal cancer	1.03e-05	3.67e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	1.03e-05	3.66e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—MYC—esophageal cancer	1.03e-05	3.66e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.03e-05	3.64e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	1.02e-05	3.62e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	1.01e-05	3.58e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—CCND1—esophageal cancer	1.01e-05	3.58e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—EGFR—esophageal cancer	1.01e-05	3.58e-05	CbGpPWpGaD
Doxepin—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.01e-05	3.57e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	1e-05	3.56e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—CCND1—esophageal cancer	1e-05	3.56e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—ERBB2—esophageal cancer	1e-05	3.55e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	1e-05	3.55e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	9.98e-06	3.54e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—MYC—esophageal cancer	9.97e-06	3.54e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—PIK3CA—esophageal cancer	9.95e-06	3.53e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CYP1B1—esophageal cancer	9.91e-06	3.52e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—MYC—esophageal cancer	9.87e-06	3.5e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	9.86e-06	3.5e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—PIK3CA—esophageal cancer	9.86e-06	3.5e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—ERBB2—esophageal cancer	9.84e-06	3.49e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	9.83e-06	3.49e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	9.8e-06	3.48e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—ERBB2—esophageal cancer	9.77e-06	3.47e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	9.75e-06	3.46e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—EGFR—esophageal cancer	9.75e-06	3.46e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	9.75e-06	3.46e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	9.7e-06	3.44e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—ERBB2—esophageal cancer	9.68e-06	3.43e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—EGFR—esophageal cancer	9.65e-06	3.42e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	9.65e-06	3.42e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—EP300—esophageal cancer	9.61e-06	3.41e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	9.6e-06	3.41e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	9.59e-06	3.4e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—EP300—esophageal cancer	9.51e-06	3.37e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	9.44e-06	3.35e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.36e-06	3.32e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CYP19A1—esophageal cancer	9.32e-06	3.31e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	9.29e-06	3.29e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—EP300—esophageal cancer	9.28e-06	3.29e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—MYC—esophageal cancer	9.28e-06	3.29e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	9.27e-06	3.29e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—EP300—esophageal cancer	9.23e-06	3.27e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	9.13e-06	3.24e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—EGFR—esophageal cancer	9.07e-06	3.22e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—CREBBP—esophageal cancer	9.07e-06	3.22e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—EP300—esophageal cancer	8.98e-06	3.18e-05	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—TP53—esophageal cancer	8.97e-06	3.18e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	8.97e-06	3.18e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—CREBBP—esophageal cancer	8.86e-06	3.14e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—CCND1—esophageal cancer	8.85e-06	3.14e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—EP300—esophageal cancer	8.84e-06	3.13e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—PIK3CA—esophageal cancer	8.75e-06	3.1e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—EP300—esophageal cancer	8.72e-06	3.09e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—CCND1—esophageal cancer	8.71e-06	3.09e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—CCND1—esophageal cancer	8.69e-06	3.08e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—CCND1—esophageal cancer	8.66e-06	3.07e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—CCND1—esophageal cancer	8.63e-06	3.06e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	8.56e-06	3.04e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—CCND1—esophageal cancer	8.55e-06	3.03e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	8.53e-06	3.02e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—HMOX1—esophageal cancer	8.51e-06	3.02e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	8.46e-06	3e-05	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—TP53—esophageal cancer	8.46e-06	3e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	8.42e-06	2.99e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	8.41e-06	2.98e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	8.38e-06	2.97e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—PIK3CA—esophageal cancer	8.38e-06	2.97e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—MYC—esophageal cancer	8.38e-06	2.97e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—CDKN1A—esophageal cancer	8.35e-06	2.96e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—CREBBP—esophageal cancer	8.34e-06	2.96e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—CREBBP—esophageal cancer	8.27e-06	2.93e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—CDKN1A—esophageal cancer	8.27e-06	2.93e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	8.25e-06	2.93e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	8.19e-06	2.91e-05	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—TP53—esophageal cancer	8.19e-06	2.9e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—ABCB1—esophageal cancer	8.16e-06	2.9e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—EP300—esophageal cancer	8.15e-06	2.89e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—NOS3—esophageal cancer	8.12e-06	2.88e-05	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—TP53—esophageal cancer	8.1e-06	2.87e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—MYC—esophageal cancer	8.09e-06	2.87e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—MYC—esophageal cancer	8.04e-06	2.85e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—EP300—esophageal cancer	8.02e-06	2.84e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—EP300—esophageal cancer	8e-06	2.84e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8e-06	2.84e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—EP300—esophageal cancer	7.97e-06	2.83e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—EP300—esophageal cancer	7.95e-06	2.82e-05	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—PIK3CA—esophageal cancer	7.94e-06	2.82e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—NOS3—esophageal cancer	7.93e-06	2.81e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	7.92e-06	2.81e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—EGFR—esophageal cancer	7.91e-06	2.81e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—PIK3CA—esophageal cancer	7.88e-06	2.79e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—EP300—esophageal cancer	7.87e-06	2.79e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—EGFR—esophageal cancer	7.87e-06	2.79e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—EP300—esophageal cancer	7.85e-06	2.78e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—MYC—esophageal cancer	7.82e-06	2.78e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—MYC—esophageal cancer	7.7e-06	2.73e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	7.66e-06	2.72e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	7.65e-06	2.71e-05	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—TP53—esophageal cancer	7.62e-06	2.7e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	7.53e-06	2.67e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—NOS3—esophageal cancer	7.47e-06	2.65e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PTGS2—esophageal cancer	7.43e-06	2.64e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—NOS3—esophageal cancer	7.41e-06	2.63e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—EP300—esophageal cancer	7.29e-06	2.59e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PTGS2—esophageal cancer	7.25e-06	2.57e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	7.11e-06	2.52e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—MYC—esophageal cancer	7.1e-06	2.52e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—CREBBP—esophageal cancer	7.07e-06	2.51e-05	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—PIK3CA—esophageal cancer	7.03e-06	2.49e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—MYC—esophageal cancer	6.99e-06	2.48e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—MYC—esophageal cancer	6.97e-06	2.47e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—MYC—esophageal cancer	6.95e-06	2.46e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—EGFR—esophageal cancer	6.94e-06	2.46e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—MYC—esophageal cancer	6.93e-06	2.46e-05	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—TP53—esophageal cancer	6.88e-06	2.44e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	6.86e-06	2.43e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—MYC—esophageal cancer	6.86e-06	2.43e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—MYC—esophageal cancer	6.84e-06	2.43e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PTGS2—esophageal cancer	6.83e-06	2.42e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—EGFR—esophageal cancer	6.83e-06	2.42e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	6.83e-06	2.42e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—EGFR—esophageal cancer	6.82e-06	2.42e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—EGFR—esophageal cancer	6.8e-06	2.41e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PTGS2—esophageal cancer	6.77e-06	2.4e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—EGFR—esophageal cancer	6.77e-06	2.4e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—EGFR—esophageal cancer	6.71e-06	2.38e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	6.69e-06	2.37e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	6.64e-06	2.36e-05	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—TP53—esophageal cancer	6.64e-06	2.36e-05	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—TP53—esophageal cancer	6.61e-06	2.34e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	6.54e-06	2.32e-05	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—PIK3CA—esophageal cancer	6.45e-06	2.29e-05	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—TP53—esophageal cancer	6.43e-06	2.28e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—MYC—esophageal cancer	6.36e-06	2.25e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—NOS3—esophageal cancer	6.33e-06	2.25e-05	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—TP53—esophageal cancer	6.32e-06	2.24e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	6.22e-06	2.2e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—EP300—esophageal cancer	6.18e-06	2.19e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—EP300—esophageal cancer	6.03e-06	2.14e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	6.03e-06	2.14e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	5.93e-06	2.1e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	5.92e-06	2.1e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	5.9e-06	2.09e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—PIK3CA—esophageal cancer	5.88e-06	2.09e-05	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—TP53—esophageal cancer	5.83e-06	2.07e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—PIK3CA—esophageal cancer	5.82e-06	2.07e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	5.81e-06	2.06e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PTGS2—esophageal cancer	5.79e-06	2.05e-05	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—TP53—esophageal cancer	5.74e-06	2.03e-05	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—TP53—esophageal cancer	5.72e-06	2.03e-05	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—TP53—esophageal cancer	5.71e-06	2.02e-05	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—TP53—esophageal cancer	5.69e-06	2.02e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—EP300—esophageal cancer	5.68e-06	2.02e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—EP300—esophageal cancer	5.63e-06	2e-05	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—TP53—esophageal cancer	5.63e-06	2e-05	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—TP53—esophageal cancer	5.62e-06	1.99e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.46e-06	1.94e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	5.39e-06	1.91e-05	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—TP53—esophageal cancer	5.22e-06	1.85e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—NOS3—esophageal cancer	4.88e-06	1.73e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—EP300—esophageal cancer	4.81e-06	1.71e-05	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—PIK3CA—esophageal cancer	4.57e-06	1.62e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.47e-06	1.58e-05	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—PIK3CA—esophageal cancer	4.46e-06	1.58e-05	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.2e-06	1.49e-05	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—PIK3CA—esophageal cancer	4.17e-06	1.48e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—EP300—esophageal cancer	3.72e-06	1.32e-05	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—PIK3CA—esophageal cancer	3.56e-06	1.26e-05	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.75e-06	9.75e-06	CbGpPWpGaD
